Voyager Therapeutics, Inc. (NASDAQ:VYGR – Free Report) – Equities research analysts at Wedbush decreased their FY2023 earnings per share estimates for shares of Voyager Therapeutics in a note issued to investors on Tuesday, November 7th. Wedbush analyst L. Chico now expects that the company will post earnings of $1.15 per share for the year, down from their previous estimate of $1.23. The consensus estimate for Voyager Therapeutics’ current full-year earnings is $1.12 per share. Wedbush also issued estimates for Voyager Therapeutics’ Q4 2023 earnings at ($0.61) EPS, Q1 2024 earnings at ($0.74) EPS, Q2 2024 earnings at ($0.76) EPS, Q3 2024 earnings at ($0.58) EPS, Q4 2024 earnings at ($0.60) EPS and FY2024 earnings at ($2.63) EPS.
Several other research analysts have also commented on the company. Oppenheimer reissued an “outperform” rating and issued a $16.00 price target on shares of Voyager Therapeutics in a research report on Monday, August 7th. StockNews.com began coverage on Voyager Therapeutics in a research note on Thursday, October 5th. They set a “hold” rating on the stock. Finally, Chardan Capital restated a “neutral” rating on shares of Voyager Therapeutics in a research note on Monday, September 18th. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $17.00.
Voyager Therapeutics Trading Down 6.3 %
VYGR opened at $6.38 on Thursday. The firm has a market cap of $280.08 million, a price-to-earnings ratio of 5.19 and a beta of 1.01. Voyager Therapeutics has a 12 month low of $5.03 and a 12 month high of $14.34. The stock has a fifty day moving average price of $7.58 and a 200-day moving average price of $9.41.
Hedge Funds Weigh In On Voyager Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of the stock. Ameritas Investment Partners Inc. acquired a new position in Voyager Therapeutics in the 2nd quarter worth about $30,000. Gladius Capital Management LP acquired a new position in shares of Voyager Therapeutics during the third quarter valued at approximately $25,000. UBS Group AG acquired a new position in shares of Voyager Therapeutics during the first quarter valued at approximately $39,000. BNP Paribas Arbitrage SNC raised its holdings in shares of Voyager Therapeutics by 12,170.6% during the second quarter. BNP Paribas Arbitrage SNC now owns 8,344 shares of the company’s stock valued at $96,000 after acquiring an additional 8,276 shares during the last quarter. Finally, PDT Partners LLC acquired a new position in shares of Voyager Therapeutics during the second quarter valued at approximately $60,000. Institutional investors and hedge funds own 58.81% of the company’s stock.
Insider Buying and Selling at Voyager Therapeutics
In other Voyager Therapeutics news, insider Todd Alfred Carter sold 10,500 shares of the business’s stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $8.16, for a total transaction of $85,680.00. Following the sale, the insider now owns 54,360 shares in the company, valued at approximately $443,577.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CFO Peter P. Pfreundschuh sold 13,567 shares of the business’s stock in a transaction dated Tuesday, October 3rd. The stock was sold at an average price of $6.99, for a total value of $94,833.33. Following the completion of the transaction, the chief financial officer now owns 149,433 shares of the company’s stock, valued at approximately $1,044,536.67. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Todd Alfred Carter sold 10,500 shares of the business’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $8.16, for a total value of $85,680.00. Following the completion of the transaction, the insider now directly owns 54,360 shares of the company’s stock, valued at approximately $443,577.60. The disclosure for this sale can be found here. Company insiders own 4.70% of the company’s stock.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease.
- Five stocks we like better than Voyager Therapeutics
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Institutional activity provides a bottom for gaming stocks
- Short Selling: How to Short a Stock
- Coca-Cola EuroPacific Partners is a tasty play on Coke
- What is the S&P 500 and How It is Distinct from Other Indexes
- 3 reasons Qualcomm might be the easiest buy this month
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.